Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Sequenom Sells Bioscience Business to Agena

Published: Friday, May 30, 2014
Last Updated: Monday, June 02, 2014
Bookmark and Share
Sequenom, Inc completes the sale of its Bioscience business to Agena Bioscience, a portfolio company of Telegraph Hill Partners.

The terms of the agreement provide for a purchase price of $31.8 million, subject to certain adjustments, and Sequenom may also receive up to $4 million in contingent consideration upon the achievement of certain regulatory and sales milestones. Agena Bioscience also assumed certain liabilities related to the Bioscience business, which does not include any portion of Sequenom's bank debt or convertible notes outstanding. The facility lease for its Bioscience location in San Diego was also assumed by Agena Bioscience. All of the current Bioscience employees will be offered employment by Agena Bioscience. 

"We are pleased to sell the business to Agena Bioscience and Telegraph Hill Partners as they plan to invest in the growth of the Bioscience business to achieve its full potential. This sale strengthens our balance sheet, and will enable us to focus exclusively on our Sequenom Laboratories business as we work toward achieving profitability," said Harry F. Hixson, Jr., Chairman and CEO of Sequenom. 

The acquired business will continue to manufacture and sell the MassARRAY® System, a proprietary mass spectrometry-based genetic analysis instrument and associated products and services that provide research and clinical investigators with economical high multiplexing, high volume results, and precise quantification in a well-established platform technology. 


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Sequenom Announces Launch of SensiGene Fetal(XY) - Fetal Sex Determination Test
This is the company's second laboratory developed test powered by its SEQureDx™ technology.
Wednesday, February 17, 2010
Sequenom Licenses Worldwide Rights to Develop Age-Related Macular Degeneration Diagnostic Test
Agreement covers extensive IP rights for AMD-related genetic variants that have been confirmed in multiple clinical studies around the world.
Wednesday, February 10, 2010
University of Michigan Study Shows SEQUENOM's MassARRAY Technology Identifies HPV Infections Missed by Standard Hybridization Test
New Study Uncovers Significant Proportion of Potential False Negatives in Widely Used HPV DNA Test which could lead to Cervical Cancer
Tuesday, July 14, 2009
SEQUENOM Announces Cost Cutting Initiative in Genetic Analysis Business
Company implements cost cutting initiatives to ensure the GA unit remains financially strong and approaches cash flow break-even.
Monday, April 27, 2009
Sequenom Selects PDI to Provide Sales Team for Launch of Noninvasive Prenatal Screening Tests
PDI to support the commercialization of SCMM's fetal Rhesus D genotyping test from a maternal blood sample.
Wednesday, March 04, 2009
Sequenom Announces Findings on Methylation Markers and RNA-SNP Markers
Company provides additional details on SEQureDx Trisomy 21 technology performance data.
Wednesday, February 04, 2009
Sequenom Announces Positive Data on Down Syndrome Detection and Unveils DNA Approach to Prenatal Diagnostics
Data continue to support market potential for Sequenom prenatal franchise; Down syndrome test on track for launch in June 2009.
Monday, February 02, 2009
Sequenom Announces Exclusive Licensing Agreement with Xenomics for Noninvasive Prenatal Diagnostics Using Transrenal DNA
Sequenom, Inc. announced that it has licensed from Xenomics, Inc. exclusive rights to patents (U.S. Patents 6,251,638 and RE 39,920, European Patent EP 0920539) for prenatal research and diagnostic products developed using fetal nucleic acids found in maternal urine.
Thursday, October 30, 2008
Sequenom Announces Licensing Agreement with Genomic Nanosystems
The license provides Sequenom with the exclusive right to use digital PCR methods for noninvasive prenatal diagnostics and analysis.
Tuesday, September 23, 2008
Sequenom Acquires License to Digital PCR and Other Noninvasive Prenatal Diagnostic Intellectual Property
The license expands Sequenom's IP portfolio of noninvasive prenatal diagnostic methods using fetal nucleic acids obtained from a maternal sample.
Wednesday, September 17, 2008
Sequenom Announces Results of Screening Studies for Down Syndrome
Company announces positive results from screening studies using the its noninvasive circulating cell-free fetal nucleic acid SEQureDx™ Technology.
Monday, June 09, 2008
Sequenom Announces Multiple MassARRAY Systems Sales in China
Beijing Genomics Institute which plans to use the MassARRAY system for its advanced research in viral genetics and human genetic projects.
Thursday, March 20, 2008
Sequenom Announces Multiple MassARRAY Systems Sales in China
Sequenom, Inc. has announced the sales of multiple MassARRAY(R) systems in China.
Wednesday, March 12, 2008
Sequenom Announces Key Milestone in Development of Noninvasive Prenatal Down Syndrome Test
Sequenom develops a noninvasive test for Trisomy 21, Down syndrome, that will incorporate multiple RNA fetal markers.
Thursday, February 21, 2008
Sequenom and NAFTNet to Conduct Fetal Rhesus D Study in Collaboration with Baylor College of Medicine
Sequenom to conduct a multi-center fetal Rhesus D (RhD) genotype study at centers affiliated with the North American Fetal Therapy Network.
Wednesday, January 30, 2008
Scientific News
Liquid Biopsies: Utilization of Circulating Biomarkers for Minimally Invasive Diagnostics Development
Market Trends in Biofluid-based Liquid Biopsies: Deploying Circulating Biomarkers in the Clinic. Enal Razvi, Ph.D., Managing Director, Select Biosciences, Inc.
Lab-on-a-Chip Offers Promise for TB and Asthma Patients
A device to mix liquids using ultrasonics is the first and most difficult component in a miniaturized system for low-cost analysis of sputum from patients with pulmonary diseases such as tuberculosis and asthma.
Intracellular Microlasers Could Allow Precise Labeling of up to a Trillion Individual Cells
MGH investigators have induced structures incorporated within individual cells to produce laser light at wavelengths that differ based on the size, shape and composition of each microlaser, allowing precise labeling of individual cells.
Real-Time Imaging of Lung Lesions During Surgery
Targeted molecular agents cause lung adenocarcinomas to fluoresce during surgery, according to pilot report.
Watching a Tumour Grow in Real-Time
Researchers from the University of Freiburg have gained new insight into the phases of breast cancer growth.
Protein Related to Long Term Traumatic Brain Injury Complications Discovered
NIH-study shows protein found at higher levels in military members who have suffered multiple TBIs.
Childhood Cancer Cells Drain Immune System’s Batteries
Cancer cells in neuroblastoma contain a molecule that breaks down a key energy source for the body’s immune cells, leaving them too physically drained to fight the disease.
Urine Proteins Point to Early-Stage Pancreatic Cancer
A combination of three proteins found at high levels in urine can accurately detect early-stage pancreatic cancer, researchers at the BCI have shown.
Researcher Discovers Trigger of Deadly Melanoma
New research sheds light on the precise trigger that causes melanoma cancer cells to transform from non-invasive cells to invasive killer agents, pinpointing the precise place in the process where "traveling" cancer turns lethal.
New Vaccine For Chlamydia to Use Synthetic Biology
Prokarium Ltd, a biotechnology company developing transformational oral vaccines, have announced new funding from SynbiCITE, the UK’s Innovation and Knowledge Centre for Synthetic Biology.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!